Initial data regarding tumor antigen escape have emerged predominantly from evaluating a patient who received anti-CD19 CARs with the complete or partial loss of CD19 expression leading to resistance to anti-CD19 CAR [279]. This evidence concerns the gene CD19 and neoplasm.